Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
7.18
+0.27 (3.91%)
At close: Oct 15, 2026, 4:00 PM EDT
7.18
0.00 (-0.04%)
After-hours: Oct 15, 2026, 7:30 PM EDT
Emergent BioSolutions Revenue
Emergent BioSolutions had revenue of $234.30M in the quarter ending June 30, 2026, with 66.29% growth. This brings the company's revenue in the last twelve months to $770.20M, down -9.56% year-over-year. In the year 2025, Emergent BioSolutions had annual revenue of $742.90M, down -28.81%. That makes Emergent BioSolutions the 8,856th largest company in the world by revenue and 1,973rd in the United States.
Revenue (ttm)
$770.20M
Revenue Growth
-9.56%
P/S Ratio
0.48
Revenue / Employee
$855,778
Employees
900
Market Cap
368.14M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 742.90M | -300.70M | -28.81% |
| Dec 31, 2024 | 1.04B | -5.70M | -0.54% |
| Dec 31, 2023 | 1.05B | -68.20M | -6.10% |
| Dec 31, 2022 | 1.12B | -656.10M | -36.99% |
| Dec 31, 2021 | 1.77B | 196.30M | 12.45% |
| Dec 31, 2020 | 1.58B | 471.30M | 42.61% |
| Dec 31, 2019 | 1.11B | 323.60M | 41.36% |
| Dec 31, 2018 | 782.40M | 221.50M | 39.49% |
| Dec 31, 2017 | 560.90M | 72.10M | 14.75% |
| Dec 31, 2016 | 488.80M | -531.00K | -0.11% |
| Dec 31, 2015 | 489.33M | 84.87M | 20.98% |
| Dec 31, 2014 | 404.47M | 91.72M | 29.33% |
| Dec 31, 2013 | 312.75M | 30.86M | 10.95% |
| Dec 31, 2012 | 281.89M | 8.50M | 3.11% |
| Dec 31, 2011 | 273.38M | -12.79M | -4.47% |
| Dec 31, 2010 | 286.17M | 51.39M | 21.89% |
| Dec 31, 2009 | 234.79M | 56.23M | 31.49% |
| Dec 31, 2008 | 178.55M | -4.36M | -2.38% |
| Dec 31, 2007 | 182.92M | 30.18M | 19.76% |
| Dec 31, 2006 | 152.73M | 22.04M | 16.87% |
| Dec 31, 2005 | 130.69M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 963.10M |
| Evotec SE | 819.47M |
| Evolus | 316.49M |
| Aurora Cannabis | 221.16M |
| Canopy Growth | 206.77M |
| Kamada | 191.85M |
| Glass House Brands | 176.98M |
| Anika Therapeutics | 120.65M |
EBS News
- 16 hours ago - Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026 - Business Wire
- 10 days ago - Russian plague outbreak could boost these under-the-radar pharma stocks - Invezz
- 4 weeks ago - Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility - GlobeNewsWire
- 4 weeks ago - Emergent BioSolutions Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 6 weeks ago - Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes - GlobeNewsWire
- 6 weeks ago - Emergent BioSolutions announces $24M modification from BARDA - TheFly
- 6 weeks ago - Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) - GlobeNewsWire
- 6 weeks ago - Emergent awarded standing offer by Government of Canada for Narcan Nasal Spray - TheFly